Texas Senate Bill SB694

Texas 2015 - 84th Regular

Caption

Relating to authorizing patients with certain terminal illnesses to access certain investigational drugs, biological products, and devices that are in clinical trials.

Impact

If enacted, SB694 would amend existing healthcare laws, specifically by adding a new chapter to the Health and Safety Code that will facilitate access to investigational treatments for defined patient groups. It permits physicians to recommend investigational products, assuming patients meet specific eligibility criteria, and establishes a framework for informed consent. Importantly, the legislation emphasizes that state officials cannot block patients' access to these investigational options.

Summary

SB694, known as the Right To Try Act, aims to empower patients with terminal illnesses by allowing them access to investigational drugs, biological products, and devices that are still undergoing clinical trials. The bill acknowledges that patients facing terminal illnesses often do not have the luxury of waiting for long FDA approval processes and emphasizes the need for patients to have the fundamental right to pursue potentially life-saving treatments that are not yet available to the general public.

Sentiment

The sentiment surrounding SB694 tends to be supportive, particularly among patient advocacy groups who argue for the importance of giving individuals facing terminal diagnoses the choice and opportunity to seek experimental treatments. However, there are concerns from some medical professionals and ethicists about the ramifications of allowing access to unproven therapies, including issues of patient safety and potential exploitation.

Contention

Notable points of contention revolve around the balance between patient autonomy and safety. Critics argue that while the intentions of the bill are noble, the lack of regulation could lead to patients being exploited and receiving treatments without adequate oversight. There are also concerns about the potential implications for healthcare providers, specifically regarding the liability for any adverse effects arising from the use of investigational treatments, as the bill absolves manufacturers from certain liabilities related to these therapies.